The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
The purpose of this prospective interventional study is to gain clinical experience using
convalescent plasma transfusion administered to critically ill patients with COVID-19.
1 To study the efficacy of plasma from patients recovered from COVID-19 infection with a high
neutralizing antibody titer (NAT) as treatment for individuals who are critically ill with
COVID-19.
2. Determine if the antibodies from convalescent plasma will suppress virus load in
critically ill patients with COVID-19.
Biological: Convalescent Plasma
treatment with 2 Units of convalescent plasma
Inclusion Criteria:
- All genders
- Age > 18 yrs and < 90 yrs
- Must have laboratory confirmed COVID-19
- Must provide informed consent
- Must have severe or immediately life-threatening COVID-19,
Severe disease is defined as:
- dyspnea,
- respiratory frequency ≥ 30/min,
- blood oxygen saturation ≤ 93%,
- partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300
- lung infiltrates > 50% within 24 to 48 hours
Life-threatening disease is defined as:
- respiratory failure,
- septic shock
- multiple organ dysfunction or failure
Exclusion Criteria:
- No gender exclusion
- Age < 18 yrs and > 90 yrs
- COVID-19 negative
Trinity Health Of New England
Hartford, Connecticut, United States
Latha Dulipsingh, MD, Principal Investigator
Saint Francis Hospital and Medical Centerr/Trinity Health Of New England